ATLCAR.CD138
/ UNC Lineberger Comprehensive Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 03, 2025
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=25 | Active, not recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2030 ➔ Aug 2039 | Trial primary completion date: Jul 2026 ➔ Oct 2024
Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
July 12, 2024
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=33 | Recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial completion date: Jun 2028 ➔ Jun 2030 | Trial primary completion date: Jul 2024 ➔ Jul 2026
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
January 11, 2023
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=33 | Recruiting | Sponsor: UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2032 ➔ Jun 2028 | Trial primary completion date: Nov 2022 ➔ Jul 2024
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1